10-K Filing

INSIGHT MOLECULAR DIAGNOSTICS INC. CIK: 1642380 FY 2016

Filing Information

Form Type	10-K
Accession Number	`0001140361-17-009369`
Period End Date	20161231
Filing Date	20170227
Fiscal Year	2016
Fiscal Period	FY
XBRL Instance	ocx-20161231.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 66 Income Statement 30 Cash Flow Statement 86 Stockholders Equity 36 Comprehensive Income 12

Balance Sheet 66 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, par value (in dollars per share)	`PreferredStockNoParValue`	-	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$10.17M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$257.00K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$8.00M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$101.00K	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockNoParValue`	-	USD	Point-in-time
BioTime shares held as available-for-sale securities, at fair value	`AvailableForSaleSecuritiesEquitySecuritiesCurrent`	$2.54M	USD	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
BioTime shares held as available-for-sale securities, at fair value	`AvailableForSaleSecuritiesEquitySecuritiesCurrent`	$2.24M	USD	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$388.00K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$285.00K	USD	Point-in-time
Preferred stock, shares issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Total current assets	`AssetsCurrent`	$12.70M	USD	Point-in-time
Preferred stock, shares outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred stock, shares outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Total current assets	`AssetsCurrent`	$10.93M	USD	Point-in-time
Common shares, par value (in dollars per share)	`CommonStockNoParValue`	-	USD	Point-in-time
Common shares, par value (in dollars per share)	`CommonStockNoParValue`	-	USD	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	50.00M	shares	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$1.23M	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$988.00K	USD	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	50.00M	shares	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	25.39M	shares	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	28.74M	shares	Point-in-time
Equipment and furniture, net	`PropertyPlantAndEquipmentNet`	$688.00K	USD	Point-in-time
Equipment and furniture, net	`PropertyPlantAndEquipmentNet`	$576.00K	USD	Point-in-time
Deposits	`DepositsAssetsNoncurrent`	$75.00K	USD	Point-in-time
Common shares, shares outstanding (in shares)	`CommonStockSharesOutstanding`	25.39M	shares	Point-in-time
Common shares, shares outstanding (in shares)	`CommonStockSharesOutstanding`	28.74M	shares	Point-in-time
Deposits	`DepositsAssetsNoncurrent`	-	USD	Point-in-time
TOTAL ASSETS	`Assets`	$14.45M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$12.73M	USD	Point-in-time
Amount due to parent, BioTime	`DueToRelatedPartiesCurrent`	$807.00K	USD	Point-in-time
Amount due to parent, BioTime	`DueToRelatedPartiesCurrent`	$2.70M	USD	Point-in-time
Amount due to affiliates	`DueToAffiliateCurrent`	$40.00K	USD	Point-in-time
Amount due to affiliates	`DueToAffiliateCurrent`	$151.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$422.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$285.00K	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$797.00K	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$1.18M	USD	Point-in-time
Capital lease liability	`CapitalLeaseObligationsCurrent`	-	USD	Point-in-time
Capital lease liability	`CapitalLeaseObligationsCurrent`	$202.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$2.31M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$4.28M	USD	Point-in-time
Capital lease liability	`CapitalLeaseObligationsNoncurrent`	$310.00K	USD	Point-in-time
Capital lease liability	`CapitalLeaseObligationsNoncurrent`	-	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$2.31M	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$4.58M	USD	Point-in-time
Commitments and contingencies (see Note 9)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (see Note 9)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock, no par value, 5,000 shares authorized; none issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, no par value, 5,000 shares authorized; none issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Common stock, no par value, 50,000 shares authorized; 28,737 and 25,391 shares issued and outstanding at December 31, 2016 and 2015, respectively	`CommonStockValue`	$45.82M	USD	Point-in-time
Common stock, no par value, 50,000 shares authorized; 28,737 and 25,391 shares issued and outstanding at December 31, 2016 and 2015, respectively	`CommonStockValue`	$34.90M	USD	Point-in-time
Accumulated other comprehensive loss on available-for-sale securities	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-350.00K	USD	Point-in-time
Accumulated other comprehensive loss on available-for-sale securities	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-654.00K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-24.13M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-35.30M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$10.42M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$-1.07M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$9.86M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$3.62M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$14.45M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$12.73M	USD	Point-in-time

Income Statement 30 line items

Line Item	Tag	Value	Unit	Period
Research and development	`ResearchAndDevelopmentExpense`	$4.53M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$5.68M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$3.96M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$1.01M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$4.19M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$5.46M	USD	Annual
Total operating expenses	`OperatingExpenses`	$11.14M	USD	Annual
Total operating expenses	`OperatingExpenses`	$4.97M	USD	Annual
Total operating expenses	`OperatingExpenses`	$8.72M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-8.72M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-11.14M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-4.97M	USD	Annual
Interest expense, net	`InterestIncomeExpenseNet`	$-2.00K	USD	Annual
Interest expense, net	`InterestIncomeExpenseNet`	$-19.00K	USD	Annual
Interest expense, net	`InterestIncomeExpenseNet`	$-28.00K	USD	Annual
Other income (expenses), net	`OtherNonoperatingIncomeExpense`	$-11.00K	USD	Annual
Other income (expenses), net	`OtherNonoperatingIncomeExpense`	$2.00K	USD	Annual
Other income (expenses), net	`OtherNonoperatingIncomeExpense`	-	USD	Annual
Total other expenses, net	`NonoperatingIncomeExpense`	$-17.00K	USD	Annual
Total other expenses, net	`NonoperatingIncomeExpense`	$-28.00K	USD	Annual
Total other expenses, net	`NonoperatingIncomeExpense`	$-13.00K	USD	Annual
NET LOSS	`NetIncomeLoss`	$-11.17M	USD	Annual
NET LOSS	`NetIncomeLoss`	$-8.73M	USD	Annual
NET LOSS	`NetIncomeLoss`	$-4.99M	USD	Annual
Basic and diluted net loss per share (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.27	USD	Annual
Basic and diluted net loss per share (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.42	USD	Annual
Basic and diluted net loss per share (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.42	USD	Annual
Weighted average shares outstanding: basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	18.20M	shares	Annual
Weighted average shares outstanding: basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	26.53M	shares	Annual
Weighted average shares outstanding: basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	21.01M	shares	Annual

Cash Flow Statement 86 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-11.17M	USD	Annual
Net loss	`NetIncomeLoss`	$-8.73M	USD	Annual
Net loss	`NetIncomeLoss`	$-4.99M	USD	Annual
Depreciation expense	`Depreciation`	$39.00K	USD	Annual
Depreciation expense	`Depreciation`	$41.00K	USD	Annual
Depreciation expense	`Depreciation`	$145.00K	USD	Annual
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$242.00K	USD	Annual
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$242.00K	USD	Annual
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$242.00K	USD	Annual
Stock-based compensation	`AllocatedShareBasedCompensationExpense`	$922.00K	USD	Annual
Stock-based compensation	`AllocatedShareBasedCompensationExpense`	$1.81M	USD	Annual
Stock-based compensation	`AllocatedShareBasedCompensationExpense`	$318.00K	USD	Annual
Contingently issuable warrant expense to investors	`ContingentlyIssuableWarrantExpenseToInvestors`	-	USD	Annual
Contingently issuable warrant expense to investors	`ContingentlyIssuableWarrantExpenseToInvestors`	$65.00K	USD	Annual
Contingently issuable warrant expense to investors	`ContingentlyIssuableWarrantExpenseToInvestors`	-	USD	Annual
Interest expense	`InterestExpense`	-	USD	Annual
Interest expense	`InterestExpense`	-	USD	Annual
Interest expense	`InterestExpense`	$18.00K	USD	Annual
Amount due to parent, BioTime	`IncreaseDecreaseInDueToRelatedParties`	$1.67M	USD	Annual
Amount due to parent, BioTime	`IncreaseDecreaseInDueToRelatedParties`	$1.90M	USD	Annual
Amount due to parent, BioTime	`IncreaseDecreaseInDueToRelatedParties`	$2.82M	USD	Annual
Amount due to affiliates	`IncreaseDecreaseInDueToAffiliates`	$-115.00K	USD	Annual
Amount due to affiliates	`IncreaseDecreaseInDueToAffiliates`	$103.00K	USD	Annual
Amount due to affiliates	`IncreaseDecreaseInDueToAffiliates`	$111.00K	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-101.00K	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-6.00K	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$274.00K	USD	Annual
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$229.00K	USD	Annual
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$1.04M	USD	Annual
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$291.00K	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-4.23M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-7.52M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-1.16M	USD	Annual
Purchase of equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$9.00K	USD	Annual
Purchase of equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$500.00K	USD	Annual
Purchase of equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$106.00K	USD	Annual
Proceeds from sale of BioTime shares	`ProceedsFromSaleOfAvailableForSaleSecuritiesEquity`	$1.33M	USD	Annual
Proceeds from sale of BioTime shares	`ProceedsFromSaleOfAvailableForSaleSecuritiesEquity`	$815.00K	USD	Annual
Proceeds from sale of BioTime shares	`ProceedsFromSaleOfAvailableForSaleSecuritiesEquity`	-	USD	Annual
Security deposit	`SecurityDepositReceived`	-	USD	Annual
Security deposit	`SecurityDepositReceived`	$-75.00K	USD	Annual
Security deposit	`SecurityDepositReceived`	-	USD	Annual
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-181.00K	USD	Annual
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$1.32M	USD	Annual
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$315.00K	USD	Annual
Proceeds from exercise of options	`ProceedsFromStockOptionsExercised`	-	USD	Annual
Proceeds from exercise of options	`ProceedsFromStockOptionsExercised`	$218.00K	USD	Annual
Proceeds from exercise of options	`ProceedsFromStockOptionsExercised`	$4.00K	USD	Annual
Proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	-	USD	Annual
Proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	-	USD	Annual
Proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	$11.65M	USD	Annual
Proceeds from sale of common stock and warrants	`ProceedsFromIssuanceOfCommonSharesAndWarrants`	-	USD	Annual
Proceeds from sale of common stock and warrants	`ProceedsFromIssuanceOfCommonSharesAndWarrants`	-	USD	Annual
Proceeds from sale of common stock and warrants	`ProceedsFromIssuanceOfCommonSharesAndWarrants`	$10.55M	USD	Annual
Financing costs related to sale of common stock and warrants	`PaymentsOfStockIssuanceCosts`	$773.00K	USD	Annual
Financing costs related to sale of common stock and warrants	`PaymentsOfStockIssuanceCosts`	-	USD	Annual
Financing costs related to sale of common stock and warrants	`PaymentsOfStockIssuanceCosts`	-	USD	Annual
Repayment of capital lease obligation	`RepaymentsOfLongTermCapitalLeaseObligations`	$114.00K	USD	Annual
Repayment of capital lease obligation	`RepaymentsOfLongTermCapitalLeaseObligations`	-	USD	Annual
Repayment of capital lease obligation	`RepaymentsOfLongTermCapitalLeaseObligations`	-	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$11.65M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	-	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$9.88M	USD	Annual
NET INCREASE IN CASH AND CASH EQUIVALENTS	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$2.18M	USD	Annual
NET INCREASE IN CASH AND CASH EQUIVALENTS	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$156.00K	USD	Annual
NET INCREASE IN CASH AND CASH EQUIVALENTS	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$7.74M	USD	Annual
At beginning of the year	`CashAndCashEquivalentsAtCarryingValue`	$10.17M	USD	Point-in-time
At beginning of the year	`CashAndCashEquivalentsAtCarryingValue`	$257.00K	USD	Point-in-time
At beginning of the year	`CashAndCashEquivalentsAtCarryingValue`	$8.00M	USD	Point-in-time
At beginning of the year	`CashAndCashEquivalentsAtCarryingValue`	$101.00K	USD	Point-in-time
At end of the year	`CashAndCashEquivalentsAtCarryingValue`	$10.17M	USD	Point-in-time
At end of the year	`CashAndCashEquivalentsAtCarryingValue`	$257.00K	USD	Point-in-time
At end of the year	`CashAndCashEquivalentsAtCarryingValue`	$8.00M	USD	Point-in-time
At end of the year	`CashAndCashEquivalentsAtCarryingValue`	$101.00K	USD	Point-in-time
Equipment purchased under capital leases	`ContributionOfProperty`	-	USD	Annual
Equipment purchased under capital leases	`ContributionOfProperty`	-	USD	Annual
Equipment purchased under capital leases	`ContributionOfProperty`	$626.00K	USD	Annual
Common stock issued to BioTime for extinguishment of debt	`DebtConversionConvertedInstrumentAmount1`	$3.30M	USD	Annual
Common stock issued to BioTime for extinguishment of debt	`DebtConversionConvertedInstrumentAmount1`	-	USD	Annual
Common stock issued to BioTime for extinguishment of debt	`DebtConversionConvertedInstrumentAmount1`	-	USD	Annual
Common stock issued to BioTime upon conversion of convertible note payable and accrued interest	`CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest`	-	USD	Annual
Common stock issued to BioTime upon conversion of convertible note payable and accrued interest	`CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest`	-	USD	Annual
Common stock issued to BioTime upon conversion of convertible note payable and accrued interest	`CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest`	$3.32M	USD	Annual
Realized loss on sale of BioTime shares	`GainLossOnSaleOfEquityInvestments`	$397.00K	USD	Annual
Realized loss on sale of BioTime shares	`GainLossOnSaleOfEquityInvestments`	$569.00K	USD	Annual
Realized loss on sale of BioTime shares	`GainLossOnSaleOfEquityInvestments`	-	USD	Annual

Stockholders Equity 36 line items

Line Item	Tag	Value	Unit	Period
BALANCE	`StockholdersEquity`	$10.42M	USD	Point-in-time
BALANCE	`StockholdersEquity`	$-1.07M	USD	Point-in-time
BALANCE	`StockholdersEquity`	$9.86M	USD	Point-in-time
BALANCE	`StockholdersEquity`	$3.62M	USD	Point-in-time
BALANCE (in shares)	`CommonStockSharesOutstanding`	25.39M	shares	Point-in-time
BALANCE (in shares)	`CommonStockSharesOutstanding`	28.74M	shares	Point-in-time
Net loss	`NetIncomeLoss`	$-11.17M	USD	Annual
Net loss	`NetIncomeLoss`	$-8.73M	USD	Annual
Net loss	`NetIncomeLoss`	$-4.99M	USD	Annual
Unrealized gain (loss) on BioTime shares held as available-for-sale securities	`AvailableforsaleSecuritiesGrossUnrealizedGainLoss1`	$75.00K	USD	Annual
Unrealized gain (loss) on BioTime shares held as available-for-sale securities	`AvailableforsaleSecuritiesGrossUnrealizedGainLoss1`	$-21.00K	USD	Annual
Unrealized gain (loss) on BioTime shares held as available-for-sale securities	`AvailableforsaleSecuritiesGrossUnrealizedGainLoss1`	$-304.00K	USD	Annual
Stock-based compensation	`StockGrantedDuringPeriodValueSharebasedCompensation`	$922.00K	USD	Annual
Stock-based compensation	`StockGrantedDuringPeriodValueSharebasedCompensation`	$1.81M	USD	Annual
Stock-based compensation	`StockGrantedDuringPeriodValueSharebasedCompensation`	$318.00K	USD	Annual
Common stock issued to BioTime for extinguishment of debt	`DebtConversionConvertedInstrumentAmount1`	$3.30M	USD	Annual
Common stock issued to BioTime for extinguishment of debt	`DebtConversionConvertedInstrumentAmount1`	-	USD	Annual
Common stock issued to BioTime for extinguishment of debt	`DebtConversionConvertedInstrumentAmount1`	-	USD	Annual
Common stock issued to investors for cash	`CommonStockIssuedToInvestorsForCash`	$3.30M	USD	Annual
Common stock issued to BioTime upon conversion of BioTime convertible note payable and accrued interest	`CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest`	-	USD	Annual
Common stock issued to BioTime upon conversion of BioTime convertible note payable and accrued interest	`CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest`	-	USD	Annual
Common stock issued to BioTime upon conversion of BioTime convertible note payable and accrued interest	`CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest`	$3.32M	USD	Annual
Common stock issued to BioTime for cash	`CommonStockIssuedForCash`	$8.35M	USD	Annual
Proceeds from issuance of common stock and warrants, net of discounts and financing costs	`ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts`	$9.78M	USD	Annual
Exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$218.00K	USD	Annual
Exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$4.00K	USD	Annual
Fair value of contingently issuable warrant	`FairValueAdjustmentOfWarrants`	$65.00K	USD	Annual
OncoCyte common stock received as a dividend in kind from BioTime	`DividendsCommonStockPaidinkind`	-	USD	Annual
Transfer of realized loss into equity from sale of BioTime shares	`TransferOfRealizedLossIntoEquityFromSaleOfShares`	-	USD	Annual
Transfer of realized loss into equity from sale of BioTime shares	`TransferOfRealizedLossIntoEquityFromSaleOfShares`	-	USD	Annual
BALANCE	`StockholdersEquity`	$10.42M	USD	Point-in-time
BALANCE	`StockholdersEquity`	$-1.07M	USD	Point-in-time
BALANCE	`StockholdersEquity`	$9.86M	USD	Point-in-time
BALANCE	`StockholdersEquity`	$3.62M	USD	Point-in-time
BALANCE (in shares)	`CommonStockSharesOutstanding`	25.39M	shares	Point-in-time
BALANCE (in shares)	`CommonStockSharesOutstanding`	28.74M	shares	Point-in-time

Comprehensive Income 12 line items

Line Item	Tag	Value	Unit	Period
NET LOSS	`NetIncomeLoss`	$-11.17M	USD	Annual
NET LOSS	`NetIncomeLoss`	$-8.73M	USD	Annual
NET LOSS	`NetIncomeLoss`	$-4.99M	USD	Annual
Realized loss on sale of BioTime shares	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	$569.00K	USD	Annual
Realized loss on sale of BioTime shares	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	$397.00K	USD	Annual
Realized loss on sale of BioTime shares	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	-	USD	Annual
Unrealized (loss) gain on BioTime shares held as available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-21.00K	USD	Annual
Unrealized (loss) gain on BioTime shares held as available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-304.00K	USD	Annual
Unrealized (loss) gain on BioTime shares held as available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$75.00K	USD	Annual
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-8.26M	USD	Annual
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-11.47M	USD	Annual
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-4.44M	USD	Annual

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.